Advertisement

The Patient Advocate Perspective on Preparing for FDA Advisory Committee Presentations

Abstract

This article highlights the author’s experiences as a patient advocate serving on the Food and Drug Administration (FDA) Biological Response Modifiers Committee. It provides an overview of the National Organization for Rare Disorders and the scope of the orphan disease problem. The author explains the process of serving on an advisory committee, and highlights the important role of patient advocates in protecting the patient’s best interests.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

Author information

Correspondence to Abbey S. Meyers.

Additional information

Presented at the DIA 35th Annual Meeting, June 27–July 1, 1999, Baltimore, Maryland.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Meyers, A.S. The Patient Advocate Perspective on Preparing for FDA Advisory Committee Presentations. Ther Innov Regul Sci 34, 969–973 (2000) doi:10.1177/009286150003400330

Download citation

Key Words

  • Orphan drugs
  • FDA advisory committees
  • National Organization for Rare Disorders
  • Patients